Cooley Advises Trius Therapeutics on IPO

San Diego – August 3, 2010 -- Cooley LLP announced that it served as counsel to Trius Therapetuics, Inc. in the company's initial public offering, which priced today.  Citigroup Global Markets Inc. is the sole book-running manager, with Piper Jaffray & Co. as co-lead manager and Canaccord Genuity Inc. and JMP Securities as co-managers for the offering.  The offering consisted of 10 million shares of common stock at a price of $5.00 per share. Trius has granted the underwriters a 45-day option to purchase up to 750,000 shares of its common stock at the initial public offering price to cover over-allotments, if any.

Trius Therapeutics, Inc. is a biopharmaceutical company developing innovative antibiotics for serious, life-threatening infections.

Related Practices

©2003-2016 Cooley LLP and Cooley (UK) LLP. All rights reserved.
COOLEY® and the COOLEY LLP® logo are registered U.S. service marks of Cooley LLP.
Cooley was founded in 1920 – for our story, visit our timeline.